<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578929</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-01</org_study_id>
    <nct_id>NCT00578929</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients</brief_title>
  <official_title>Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal
      spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6
      to 11 years with a history of seasonal allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)</measure>
    <time_frame>Baseline through 2 weeks after randomization</time_frame>
    <description>Total Nasal Symptom Score comprised of scoring each of the following symptoms: runny nose, stuffy nose, itchy nose, and sneezing. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 4 individual symptom scores were then added together for a total nasal symptom score.
The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 4 individual scores averaged across all days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Reflective Total Ocular Symptom Score (TOSS)</measure>
    <time_frame>Baseline through 2 weeks after randomization</time_frame>
    <description>Total Ocular Symptom Score comprised of scoring each of the following symptoms: itchy eyes and watery eyes. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 2 individual symptom scores were then added together for a total ocular symptom score.
The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 2 individual scores averaged across all days.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2388</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Olopatadine 0.6% 1 Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olopatadine HCl 0.6% 1 spray per nostril twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle 1 spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle 1 spray per nostril twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olopatadine 0.6% 2 sprays</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olopatadine HCl 0.6% 2 sprays per nostril twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle 2 sprays</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle 2 sprays per nostril twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine Hydrochloride Nasal Spray 0.6%</intervention_name>
    <description>Olopatadine HCl 1 or 2 sprays per nostril twice daily</description>
    <arm_group_label>Olopatadine 0.6% 1 Spray</arm_group_label>
    <arm_group_label>Olopatadine 0.6% 2 sprays</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle 1 or 2 sprays per nostril twice daily</description>
    <arm_group_label>Vehicle 1 spray</arm_group_label>
    <arm_group_label>Vehicle 2 sprays</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female; minimum of 6 years of age and less than 12 years

          -  2 year history of seasonal allergic rhinitis

        Exclusion Criteria:

          -  Concurrent disease that might interfere with the investigation or evaluation of te
             study medication

          -  Confirmed diagnosis of chronic rhinosinusitis within the last year

          -  Asthma, with the exception of mild intermittent asthma

          -  Anatomical nasal deformity

          -  Nasal obstruction

          -  Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)

          -  Chronic or intermittent use of of inhaled, oral, intramuscular intravenous
             corticosteroids ot topical steroids

          -  Ocular disorder other that allergic conjunctivitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ed Tumaian</last_name>
    <role>Study Director</role>
    <affiliation>ed.tumaian@alconlabs.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenilworth/IL</name>
      <address>
        <city>Kenilworth</city>
        <state>Illinois</state>
        <zip>60043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>January 14, 2010</results_first_submitted>
  <results_first_submitted_qc>January 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2010</results_first_posted>
  <last_update_submitted>February 23, 2010</last_update_submitted>
  <last_update_submitted_qc>February 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Darrell Lange, Clinical Trial Manager</name_title>
    <organization>Alcon Research</organization>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>allergies</keyword>
  <keyword>seasonal allergies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled in the study on September 8, 2007 and the last subject exited the study on November 24, 2008. The study was conducted at medical clinics throughout the USA.</recruitment_details>
      <pre_assignment_details>Subjects completed a 4-16 day run-in period on vehicle prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olopatadine 0.6% 1 Spray</title>
          <description>Olopatadine HCl 0.6% 1 spray per nostril twice daily</description>
        </group>
        <group group_id="P2">
          <title>Vehicle 1 Spray</title>
          <description>Vehicle 1 spray per nostril twice daily</description>
        </group>
        <group group_id="P3">
          <title>Olopatadine 0.6% 2 Sprays</title>
          <description>Olopatadine HCl 0.6% 2 Sprays per nostril twice daily</description>
        </group>
        <group group_id="P4">
          <title>Vehicle 2 Sprays</title>
          <description>Vehicle 2 sprays per nostril twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vehicle Run-In Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2388"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2388"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Randomized Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="297"/>
                <participants group_id="P3" count="296"/>
                <participants group_id="P4" count="297"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="283"/>
                <participants group_id="P3" count="288"/>
                <participants group_id="P4" count="283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olopatadine 0.6% 1 Spray</title>
          <description>Olopatadine HCl 0.6% 1 spray per nostril twice daily</description>
        </group>
        <group group_id="B2">
          <title>Vehicle 1 Spray</title>
          <description>Vehicle 1 spray per nostril twice daily</description>
        </group>
        <group group_id="B3">
          <title>Olopatadine 0.6% 2 Sprays</title>
          <description>Olopatadine HCl 0.6% 2 Sprays per nostril twice daily</description>
        </group>
        <group group_id="B4">
          <title>Vehicle 2 Sprays</title>
          <description>Vehicle 2 sprays per nostril twice daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="298"/>
            <count group_id="B2" value="297"/>
            <count group_id="B3" value="296"/>
            <count group_id="B4" value="297"/>
            <count group_id="B5" value="1188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="296"/>
                    <measurement group_id="B4" value="297"/>
                    <measurement group_id="B5" value="1188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="173"/>
                    <measurement group_id="B5" value="687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)</title>
        <description>Total Nasal Symptom Score comprised of scoring each of the following symptoms: runny nose, stuffy nose, itchy nose, and sneezing. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 4 individual symptom scores were then added together for a total nasal symptom score.
The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 4 individual scores averaged across all days.</description>
        <time_frame>Baseline through 2 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olopatadine 0.6% 1 Spray</title>
            <description>Olopatadine HCl 0.6% 1 spray per nostril twice daily</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1 Spray</title>
            <description>Vehicle 1 spray per nostril twice daily</description>
          </group>
          <group group_id="O3">
            <title>Olopatadine 0.6% 2 Sprays</title>
            <description>Olopatadine HCl 0.6% 2 Sprays per nostril twice daily</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2 Sprays</title>
            <description>Vehicle 2 sprays per nostril twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)</title>
          <description>Total Nasal Symptom Score comprised of scoring each of the following symptoms: runny nose, stuffy nose, itchy nose, and sneezing. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 4 individual symptom scores were then added together for a total nasal symptom score.
The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 4 individual scores averaged across all days.</description>
          <units>Percent change of TNSS from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.10" spread="1.45"/>
                    <measurement group_id="O2" value="-18.17" spread="1.45"/>
                    <measurement group_id="O3" value="-26.35" spread="1.45"/>
                    <measurement group_id="O4" value="-21.21" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Reflective Total Ocular Symptom Score (TOSS)</title>
        <description>Total Ocular Symptom Score comprised of scoring each of the following symptoms: itchy eyes and watery eyes. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 2 individual symptom scores were then added together for a total ocular symptom score.
The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 2 individual scores averaged across all days.</description>
        <time_frame>Baseline through 2 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olopatadine 0.6% 1 Spray</title>
            <description>Olopatadine HCl 0.6% 1 spray per nostril twice daily</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1 Spray</title>
            <description>Vehicle 1 spray per nostril twice daily</description>
          </group>
          <group group_id="O3">
            <title>Olopatadine 0.6% 2 Sprays</title>
            <description>Olopatadine HCl 0.6% 2 Sprays per nostril twice daily</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2 Sprays</title>
            <description>Vehicle 2 sprays per nostril twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Reflective Total Ocular Symptom Score (TOSS)</title>
          <description>Total Ocular Symptom Score comprised of scoring each of the following symptoms: itchy eyes and watery eyes. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 2 individual symptom scores were then added together for a total ocular symptom score.
The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 2 individual scores averaged across all days.</description>
          <units>Percent change of TOSS from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.02" spread="5.11"/>
                    <measurement group_id="O2" value="-6.09" spread="5.10"/>
                    <measurement group_id="O3" value="-25.03" spread="3.33"/>
                    <measurement group_id="O4" value="-9.46" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 weeks</time_frame>
      <desc>Adverse events were collected from the time of first dose with vehicle run-in until study exit. Adverse events were both volunteered and solicited</desc>
      <group_list>
        <group group_id="E1">
          <title>Olopatadine 0.6% 1 Spray</title>
          <description>Olopatadine HCl 0.6% 1 spray per nostril twice daily</description>
        </group>
        <group group_id="E2">
          <title>Vehicle 1 Spray</title>
          <description>Vehicle 1 spray per nostril twice daily</description>
        </group>
        <group group_id="E3">
          <title>Olopatadine 0.6% 2 Sprays</title>
          <description>Olopatadine HCl 0.6% 2 Sprays per nostril twice daily</description>
        </group>
        <group group_id="E4">
          <title>Vehicle 2 Sprays</title>
          <description>Vehicle 2 sprays per nostril twice daily</description>
        </group>
        <group group_id="E5">
          <title>Vehicle Run-in Period</title>
          <description>Vehicle Run-in Period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="296"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="297"/>
                <counts group_id="E5" subjects_affected="107" subjects_at_risk="2388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="298"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="296"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E5" events="68" subjects_affected="68" subjects_at_risk="2388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="298"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="296"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E5" events="44" subjects_affected="42" subjects_at_risk="2388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor reserves the right of review 60 days prior to any publication or presentation of information related to the study. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than study data and results. The Institution and the Primary Investigator agree not to publish any study related material other than above.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

